ATE226447T1 - Anti-fas antikörper gegen rheumatische krankheiten - Google Patents

Anti-fas antikörper gegen rheumatische krankheiten

Info

Publication number
ATE226447T1
ATE226447T1 AT95115210T AT95115210T ATE226447T1 AT E226447 T1 ATE226447 T1 AT E226447T1 AT 95115210 T AT95115210 T AT 95115210T AT 95115210 T AT95115210 T AT 95115210T AT E226447 T1 ATE226447 T1 AT E226447T1
Authority
AT
Austria
Prior art keywords
fas
monoclonal antibody
antibodies against
rheumatic diseases
fas antibodies
Prior art date
Application number
AT95115210T
Other languages
English (en)
Inventor
Kusiki Nishioka
Shin Yoneyama
Original Assignee
Santen Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Santen Pharmaceutical Co Ltd filed Critical Santen Pharmaceutical Co Ltd
Application granted granted Critical
Publication of ATE226447T1 publication Critical patent/ATE226447T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT95115210T 1994-09-27 1995-09-27 Anti-fas antikörper gegen rheumatische krankheiten ATE226447T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP27013494 1994-09-27

Publications (1)

Publication Number Publication Date
ATE226447T1 true ATE226447T1 (de) 2002-11-15

Family

ID=17482032

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95115210T ATE226447T1 (de) 1994-09-27 1995-09-27 Anti-fas antikörper gegen rheumatische krankheiten

Country Status (9)

Country Link
US (1) US6086877A (de)
EP (1) EP0709097B1 (de)
KR (1) KR100371000B1 (de)
AT (1) ATE226447T1 (de)
CA (1) CA2158822C (de)
DE (1) DE69528624T2 (de)
DK (1) DK0709097T3 (de)
ES (1) ES2182860T3 (de)
PT (1) PT709097E (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5830469A (en) * 1993-10-14 1998-11-03 Immunex Corporation Fas antagonists and uses thereof
IL123756A0 (en) * 1997-03-21 1998-10-30 Sankyo Co Humanized anti-human FAS antibody
EP1087993B1 (de) 1998-06-18 2008-04-02 Imed Ab Fas peptide und antikörper zur modulierung von apoptosis
MXPA01012206A (es) 1999-05-24 2002-06-21 Sankyo Co Composiciones farmaceuticas que contienen anticuerpo anti-fas.
US6787136B1 (en) * 1999-09-03 2004-09-07 The Brigham And Women's Hospital, Inc. Methods and compositions for treatment of inflammatory disease using cadherin-11 modulating agents
AU2002210926B2 (en) 2000-10-24 2005-12-15 Shunichi Shiozawa Genomes participating in rheumatoid arthritis, method of the diagnosis thereof, method of evaluating the onset possibility thereof, diagnostic kit for detecting them and therapeutic method and remedies for rheumatoid arthritis
US20060104951A1 (en) * 2004-11-16 2006-05-18 Mountz John D Akt and regulation of RA synovial fibroblast apoptosis
US20070224184A1 (en) * 2006-02-22 2007-09-27 The Research Foundation Of The State University Of New York Method for treating cellulite
US10071143B1 (en) 2007-05-03 2018-09-11 The Research Foundation For The State University Of New York Methods for non-surgical treatment of carpal tunnel syndrome
CN105169389A (zh) * 2008-08-01 2015-12-23 阿克西斯股份有限公司 骨关节炎治疗剂及预防剂
KR101684246B1 (ko) * 2010-01-29 2016-12-08 가부시키가이샤 아크시스 변형성 관절증 치료제를 포함하는 주사제
JPWO2011093083A1 (ja) * 2010-01-29 2013-05-30 Ａｘｉｓ株式会社 変形性関節症治療又は予防用医薬組成物及びその製造方法
US8877188B2 (en) 2010-05-04 2014-11-04 The Brigham And Women's Hospital, Inc. Detection and treatment of non-dermal fibrosis
CA2861033C (en) 2012-01-12 2017-07-25 Auxilium International Holdings, Inc. Clostridium histolyticum enzymes and methods for the use thereof
WO2014066622A2 (en) 2012-10-24 2014-05-01 The Research Foundation For The State University Of New York Use of collagenase to treat glaucoma
US11097005B2 (en) 2014-12-15 2021-08-24 The Brigham And Women's Hospital, Inc. Use of cadherin-11 antagonists to treat metabolic disorders and/or increase insulin sensitivity
ES3036011T3 (en) 2017-03-01 2025-09-11 Endo Operations Ltd Apparatus and method for assessing and treating cellulite
KR20240001279A (ko) 2017-03-28 2024-01-03 엔도 벤쳐즈 리미티드 개선된 콜라게나제 생성 방법

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS58201712A (ja) * 1982-05-18 1983-11-24 Green Cross Corp:The 脂肪乳剤
JPS6051105A (ja) * 1983-08-30 1985-03-22 Green Cross Corp:The プロスタグランジン脂肪乳剤
JPH02237935A (ja) * 1989-03-10 1990-09-20 Bio Kagaku Kenkyusho:Kk エイズ処置剤
WO1991010448A1 (en) * 1990-01-19 1991-07-25 German Cancer Research Center A cell surface antigen associated with cellular apoptosis
CA2067031C (en) * 1991-04-26 2003-02-18 Shigekazu Nagata Dna coding for human cell surface antigen
CA2112473A1 (en) * 1991-07-05 1993-01-21 Patricia A. Bacha Epidermal growth factor receptor targeted molecules for treatment of inflammatory arthritis
CA2121148A1 (en) * 1992-08-19 1994-03-03 Otsuka Pharmaceutical Co., Ltd. Apoptosis regulator
WO1995010540A1 (en) * 1993-10-14 1995-04-20 Immunex Corporation Fas antagonists and uses thereof
US5830469A (en) * 1993-10-14 1998-11-03 Immunex Corporation Fas antagonists and uses thereof

Also Published As

Publication number Publication date
CA2158822A1 (en) 1996-03-28
CA2158822C (en) 2008-12-23
DK0709097T3 (da) 2003-02-24
PT709097E (pt) 2003-03-31
KR100371000B1 (ko) 2003-07-12
DE69528624D1 (de) 2002-11-28
KR960010024A (ko) 1996-04-20
ES2182860T3 (es) 2003-03-16
EP0709097B1 (de) 2002-10-23
EP0709097A1 (de) 1996-05-01
DE69528624T2 (de) 2003-06-26
US6086877A (en) 2000-07-11

Similar Documents

Publication Publication Date Title
ATE226447T1 (de) Anti-fas antikörper gegen rheumatische krankheiten
CA2310888A1 (en) Monoclonal human natural antibodies
TR200101205T1 (tr) ímmn hastalìklarìn tedavisi i‡in bir farmas”tik terkip
DE60143535D1 (de) Humane antikörper gegen cd40
BR0213846A (pt) métodos de induzir seletivamente a apoptose nas células alvo que expressam dr5, de inibir a proliferação de células alvo que expressam dr5 e de tratar um paciente tendo uma doença inflamatória ou doença autoimune, e, composição
UY28170A1 (es) Preparacion y tratamiento para las enfermedades desmielinizantes y paralisis mediante la aplicacion de agentes remielinizantes.
CY1111193T1 (el) Ανθρωπινα cdr-μοσχευμενα αντισωματα και θραυσματα αντισωματων τους
BR0317376A (pt) Anticorpo humanizado (h14.18) do anticorpo 14.18 do camundongo que se liga a gd2 e sua fusão com il-2
BR0314038A (pt) Anticorpo humano isolado, método de tratar uma doença mediada com il-1 em um paciente, composição farmacêutica, cadeias pesada e leve, e, método de mapeamento de epitopo de um antìgeno selecionado
LU91556I2 (fr) Anticorps humains reconstitués dirigés contre un récepteur de l'interleukine 6 humaine - TOCILIZUMAB
IT9068053A0 (it) Preparazione includente anticorpi monoclonali biotinilati, avidina e biotina, per la diagnosi e terapia di affezioni tumorali e suo impiego
CY2007001I2 (el) Φαρμακευτικο σκευασμα για χρηση στη θεραπεια του διαβητη
WO1994011026A3 (en) Therapeutic application of chimeric and radiolabeled antibodies to human b lymphocyte restricted differentiation antigen for treatment of b cell lymphoma
Lupton et al. An unusual presentation of dermatomyositis: the type Wong variant revisited
BR0113213A (pt) Método para diagnosticar uma doença auto-imune, anticorpo, composição de diagnóstico, e, uso do anticorpo
ATE159300T1 (de) Monoklonale antikörper gegen menschliches ige
WO2003054018A3 (en) Anti-tirc7 antibodies in therapy of inflammatory diseases
TR200103432T2 (tr) Engelleyici monoklonal VLA-1 antikoru ve enflamasyonlu hastalıkların tedavisinde kullanımı.
DE60141297D1 (de) Gegen das menschliche bst2 antigen gerichteter monoklonaler antikörper
ES2061769T3 (es) Anticuerpo monoclonal y su utilizacion.
ATE395363T1 (de) Monoklonale antikörper gegen das protein g3bp und deren verwendungen
HUP9800613A2 (hu) Humán Fas-antigén elleni humanizált antitest
BR0116010A (pt) Kit imunoterapêutico para o tratamento de tumores
EE9900010A (et) T-BAM (CD40L) tehnoloogia terapeutilised rakendused silelihasrakkudega seotud haiguste ravimiseks
Wakabayashi et al. Long-term maintenance of golimumab effectiveness for injection spacing in rheumatoid arthritis patients with low disease activity who previously received other TNF inhibitors: minimum 2-year data from an observational study

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0709097

Country of ref document: EP